HFG 1
Alternative Names: HFG-1Latest Information Update: 10 Dec 2024
Price :
$50 *
At a glance
- Originator HighField Biopharmaceuticals
- Class Antihyperglycaemics; Gene therapies; RNA
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 24 Jun 2024 Preclinical trials in Diabetes mellitus in China (SC)
- 24 Jun 2024 HighField Biopharmaceuticals plans to file an IND application with the US FDA for Diabetes Mellitus in the third quarter of 2024
- 24 Jun 2024 Adverse events and pharmacodynamics data from preclinical trials in Diabetes mellitus released by HighField Biopharmaceuticals